Mitoguazone dihydrochloride

• CAT Number: I032359
• CAS Number: 1403744-37-5
• Molecular Formula: C5H14Cl2N8
• Molecular Weight: 257.12
• Purity: 98%
• Synonyms: Mitoguazone dihydrochloride; Mitoguazone 2HCl
• Target: Liposome
• Solubility: To be determined
• Appearance: Solid powder
• Storage: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
• IUPAC Name: 3,3'-(1-Methylethane-1,2-diylidene)dicarbazamidine dihydrochloride
• InChI: InChI=1S/C5H12N8.2ClH/c1-3(11-13-5(8)9)2-10-12-4(6)7;;/h2H,1H3,(H4,6,7,12)(H4,8,9,13);2*1H/b10-2+,11-3?
• InChIKey: VVTBQCXLZQYGQE-JWICLDENSA-N
• SMILES: Cl.Cl.CC(=NNC(=N)N)C=NNC(=N)N

Mitoguazone dihydrochloride (Cat.No:I032359) is a derivative of the antineoplastic agent mitoguazone. It functions by inhibiting the enzyme ornithine decarboxylase, which is involved in polyamine synthesis. By disrupting polyamine metabolism, Mitoguazone dihydrochloride exhibits cytotoxic effects against cancer cells. It is being investigated for its potential in the treatment of various types of cancer.

Reference

1: Ferioli ME, Bottone MG, Soldani C, Pellicciari C. Administration of the antitumor drug mitoguazone protects normal thymocytes against spontaneous and etoposide-induced apoptosis. Cell Mol Life Sci. 2004 Nov;61(21):2767-73. PubMed PMID: 15549180.
2: Ferioli ME, Berselli D, Caimi S. Effect of mitoguazone on polyamine oxidase activity in rat liver. Toxicol Appl Pharmacol. 2004 Dec 1;201(2):105-11. PubMed PMID: 15541750.
3: Tulpule A, Espina BM, Pedro Santabarbara AB, Palmer M, Schiflett J, Boswell W, Smith S, Levine AM. Treatment of AIDS related non-Hodgkin’s lymphoma with combination mitoguazone dihydrochloride and low dose CHOP chemotherapy: results of a phase II study. Invest New Drugs. 2004 Jan;22(1):63-8. PubMed PMID: 14707495.
4: Ishmael DR, Chen WR, Hamilton SA, Liu H, Nordquist RE. A phase I human trial of mitoguazone and gemcitabine sequential bi-weekly treatment of cancer patients. Cancer Invest. 2003;21(4):542-9. PubMed PMID: 14533444.